ArticleJournal of diabetes research2026
16S rRNA Gene Amplicon Sequencing of Gut Microbiota in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 16S rRNA Gene Amplicon Sequencing of Gut Microbiota in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe objective of this study was to investigate the characteristics of the gut microbiota (GM) in pregnant women with gestational diabetes mellitus (GDM) and those with Type 2 diabetes mellitus (T2DM).
methodsClinical data from 33 pregnant Chinese women (15 with GDM and 18 without GDM) and 28 nonpregnant Chinese women (14 with T2DM and 14 without T2DM) were collected and statistically analyzed using SPSS software (Version 21.0). Normally distributed data were compared using an independent samples t-test, whereas nonnormally distributed data were compared using the Mann-Whitney U test. All statistical tests were two-sided, and p < 0.05 was considered significant. The 16S rRNA gene amplicons of the GM were sequenced using the Illumina HiSeq 2500 platform and compared for differences in genomic diversity, structure, and abundance using bioinformatics.
resultsSignificant differences in beta diversity were observed between pregnant women with GDM and healthy pregnant women, as well as between women with T2DM and healthy women. However, pregnant women with GDM and healthy pregnant women did not exhibit significant differences in alpha diversity, whereas women with T2DM and healthy women did. Additionally, the abundance of Firmicutes in pregnant women with GDM was higher than that in healthy pregnant women, whereas the abundances of Bacteroidetes and Lachnobacterium were lower (p < 0.05). The abundance of Phascolarctobacterium in women with T2DM was higher than that in healthy women, whereas the abundances of Proteobacteria, Actinobacteria, Roseburia, Turicibacter, and Streptococcus were lower (p < 0.05).
conclusionThe GM in pregnant women with GDM and those with T2DM differed significantly from that in the control group, providing a reference for future clinical attempts to apply intestinal microecological agents in the treatment of GDM and T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.